Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide - Wikidata - thesis-toulmin - TriplyDB

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

http://www.wikidata.org/entity/Q21195191

about

Tamoxifen Resistance: Emerging Molecular Targets Steroid hormones, steroid receptors, and breast cancer stem cells Targeting the androgen receptor in prostate and breast cancer: several new agents in development Androgen Receptor: A Complex Therapeutic Target for Breast Cancer Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.A genetic basis for the variation in the vulnerability of cancer to DNA damage.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.Coagulation factor VII is regulated by androgen receptor in breast cancer.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.Network-based prediction and knowledge mining of disease genes.Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer Emerging therapeutic targets in metastatic progression: A focus on breast cancer.The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers Role of the androgen receptor in triple-negative breast cancer.Androgen receptor as potential therapeutic target in metastatic endometrial cancer.Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.AR Signaling in Breast Cancer.Emerging strategies to overcome resistance to endocrine therapy for breast cancer.Deubiquitinases and the new therapeutic opportunities offered to cancer.Targeting the androgen receptor in breast cancer.Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.Steroid hormone receptors as prognostic markers in breast cancer.Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines.Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.Cooperative Dynamics of AR and ER Activity in Breast Cancer.

P2860

Q26739969-7CD2824A-5157-43AE-9972-8C012CCEEF62 Q26799113-9D83FA91-2A4D-462B-92BB-2F217E3D6B8B Q27009424-285F0FDC-D86A-46C8-9EB5-E87943AAFA32 Q28075188-8E9B90F4-8CAE-4697-8907-E0CC5DA42A35 Q33568421-B6465910-37FD-4084-9340-E878E786D95B Q33932665-765598D2-2974-4271-A13D-840062229F6E Q34476337-78278258-8654-434A-8468-203E6E6191D9 Q34499512-FC8A3A25-3486-400F-926C-B4ECC755F624 Q34522279-F7208AC6-AD8E-41F5-9105-05CEDACDECD2 Q34523304-5C5DE66E-98D5-415B-8E51-ADCD6D93ECE1 Q34550256-EA5942F1-9F7F-49E1-8B9E-46D0D180FA78 Q34995243-FA554B71-0235-4B91-89A0-44756475DCA0 Q34995790-21260B44-8AE9-4B4D-A7D8-51CC6712D250 Q35112392-4A4C4A05-DFB2-4F33-AD12-39A49CBF6560 Q35653174-43FA89C0-F04B-4A6C-9138-1767B431535B Q35946392-165233F6-6F55-42F4-AF2D-A092D9D468C2 Q36030567-F2BD8E47-5782-44E3-ABA5-F080EC53C2AA Q36568006-92021E60-DF84-478A-BF61-5F20DCE78A4B Q36854062-B5EC7704-8055-46BC-8D1A-A13D8A01BCBD Q36880048-B690500E-0F52-44E6-AB73-7F2A47DF1A7C Q36908403-47A13C38-1D32-4E09-BE3B-07571A927602 Q37077443-EAE48C59-12A8-40FA-B01B-8BCBFA0395CC Q37269053-5EA90AAE-205A-4B63-8B0A-144FB467B6CD Q37413869-61F311C7-7BFC-4789-9D6E-33337A7F095D Q37573317-6AB53653-2779-46DD-81C7-3C43DCA509E6 Q37580217-4246203A-6C62-4EDB-95F5-3F5A0501576C Q37629540-05FAC62C-7670-48A8-8CC8-FB9283D147F9 Q37629545-9134D46C-CC90-444C-AE08-18F90DC40504 Q37721492-A5E8A319-104A-4796-99D5-9E387B46AD8A Q38221463-9AD474B5-55EF-4D6A-A768-E06CC4404CBC Q38326071-0FDC33DB-0EE3-4CC8-98A6-2B38979DB588 Q38349376-E00F2894-3CF9-4E89-B5FF-309F9FBB4BF0 Q38399495-2AA7EA77-12B9-4779-B3A6-7BBBE848B7E0 Q38552128-12F0EFAE-A910-445C-AD4C-538366429609 Q38598704-8A15D642-E842-4009-9017-B621B70ED26B Q38608844-56F2F12C-C81C-4640-8791-6F5CB80FE4DE Q38673886-D40E8FDC-03F1-43D2-BA09-8D8CF8F25E79 Q38732349-4CBC98ED-C4CB-4624-9CF7-DBEE05B34995 Q38735015-95CBFAC1-349A-4DAB-A0CD-6AAC1CC00E00 Q38749913-CE58550E-76DD-4D6E-A0DF-0780DABA2DFA

P2860

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

http://www.wikidata.org/entity/Q21195191

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@ast

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en-gb

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@nl

type

label

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@ast

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en-gb

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@nl

prefLabel

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@ast

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en-gb

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@nl

P1433

Q21195191-5DE8F11E-7AA7-4D73-9556-7AFEBF639EF2

P1476

Q21195191-AEDE6873-502C-4338-AF79-67702C972828

P2093

Q21195191-2029F746-6633-4C29-9FB9-540720C56C2A

Q21195191-25380EF2-7388-4ADF-884F-CBB1F96AA812

Q21195191-2CDBA686-FC78-47E0-A131-29EBB2A29FF0

Q21195191-3E2EC922-FAD7-48F3-A900-57F9E640EAEF

Q21195191-531497AA-298B-43E3-9772-64C23BD9D495

Q21195191-54395B7F-1C19-43CD-B108-A75DDA9C642D

Q21195191-54A7C178-7233-4EDF-A404-DC9E389AB902

Q21195191-56632D5C-00CE-442F-B7B9-13AE75987E16

Q21195191-81A5FEBD-42BB-4B70-9C1D-D2B35C2F827C

Q21195191-84F206F6-CDE7-4311-9C6F-39A4C80CC93A

P2860

Q21195191-039C409F-7974-4983-9B48-8603632C5CE5

Q21195191-03CC5678-8DCB-4A86-811B-2C89697EBC66

Q21195191-0566B21E-6C49-427D-A048-6CB1148F9F5C

Q21195191-05E02CA7-27E5-4E78-BF9F-087D32C0C064

Q21195191-11BFB0F6-40F8-4AA4-B680-D658A0D7D7DE

Q21195191-16A21F91-0504-4CB3-AD80-DEE79BA82F35

Q21195191-284F3CBA-7914-437E-8038-81C167E53F5D

Q21195191-2C0C9B35-5E3E-4E73-BA31-131B21982930

Q21195191-2CB8A957-6B1D-4BF0-B554-ECC72BBAC7D6

Q21195191-2CD20CAC-6A20-45D2-9E63-134EF32453C2

P2888

Q21195191-18246C64-959A-4DA0-847A-C1FD85CB9BBB

P304

Q21195191-BC83E735-2DEC-49E5-88D8-A341CF5A92F5

P31

Q21195191-29932DB4-2DCD-4EB8-8305-9130D73D8C2A

P3181

Q21195191-A76DB3DE-3579-44BE-B65D-62139AD9E91B

P356

Q21195191-B19ED457-278E-42DD-82E3-8D614C2D2413

P407

Q21195191-73921DB1-1464-4CB2-99D7-A3544B8F13A3

P433

Q21195191-27443AD8-04B5-438C-A9E5-61BB5195603C

P478

Q21195191-C8585490-9D2D-4A59-B050-AABF2CC77707

P50

Q21195191-462F7274-F775-46D5-960F-D72474F189ED

Q21195191-5F5F2FAB-D550-4478-9DE1-29A9DA06A945

P577

Q21195191-34934D78-9910-406E-81A9-DB4CBFC097D6

P5875

Q21195191-9FF03897-CBF5-43E2-A1C7-D89997768D4A

P6179

Q21195191-86854353-6E07-4C0B-860C-2DF1D4EE4766

P698

Q21195191-2517F7E3-4720-46CC-9A32-BD41FDEECF61

P932

Q21195191-0A1D2D73-A0AC-4559-9064-C2FDD7BC6639

P3181

P356

P1433

Breast Cancer Research

P1476

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

@en

P2093

Andrew A Protter

http://www.w3.org/2001/XMLSchema#string

Ann D Thor

http://www.w3.org/2001/XMLSchema#string

Annie Jean

http://www.w3.org/2001/XMLSchema#string

Anthony D Elias

http://www.w3.org/2001/XMLSchema#string

Dawn R Cochrane

http://www.w3.org/2001/XMLSchema#string

Emma McCullagh

http://www.w3.org/2001/XMLSchema#string

Erin N Howe

http://www.w3.org/2001/XMLSchema#string

Francisco Gómez

http://www.w3.org/2001/XMLSchema#string

Iván E Alfaro

http://www.w3.org/2001/XMLSchema#string

Javier Guerrero

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting androgen receptor in estrogen receptor-negative breast cancer

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors

Increased survival with enzalutamide in prostate cancer after chemotherapy

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent.

Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.

Androgen receptor expression and breast cancer survival in postmenopausal women.

P2888

P304

R7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2052417

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/BCR3599

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Britta Jacobsen

Diana M Cittelly

P577

2014-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259876050

http://www.w3.org/2001/XMLSchema#string

P6179

1025546025

http://www.w3.org/2001/XMLSchema#string

P698

24451109

http://www.w3.org/2001/XMLSchema#string

P932

3978822

http://www.w3.org/2001/XMLSchema#string